Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04941573 · ClinicalTrials.gov registry record
Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI
A clinical trial, sponsored by Xemed.
- Terminated
- Registry status
- 45
- Enrollment target
NCT04941573 is a clinical trial that was terminated before completion, run by Xemed. The registered enrollment target is 45 participants.
The verdict
NCT04941573 was terminated before completion, sponsored by Xemed.
- TERMINATED
- Registry status
- 45 participants
- Enrollment target
Study Summary
This study will use Magnetic Resonance Imaging (MRI) to study the lungs of 90 volunteers using the inhaled contrast agent, hyperpolarized xenon-129. Once inhaled, this gas can provide information to imagers regarding lung functionality across specific regions of the lungs by assessing the replacement of air during the normal breathing cycle, how much oxygen is in the airspaces, and if the natural spongy tissue structure has been compromised by lung disease. Of the 90 subjects, 70 will be patients who received lung transplantation from the Penn/Temple Lung Transplant Teams and are receiving follow up treatment at HUP or TUH, 10 will be healthy control subjects who participated favorably in our HP 129Xe imaging protocol, and 10 will be patients who have been diagnosed with chronic obstructive pulmonary disease (COPD)-preferentially recruited from the Temple University COPDGene cohort, who have never undergone a lung transplant. 20 of the lung transplant recipient subjects will be patients who have received a recent clinical diagnosis of chronic lung allograft dysfunction (CLAD) prior to enrollment in our study, while the other 50 will have recently undergone their initial transplant surgery at the time of enrollment.
Interventions
- COMBINATION_PRODUCT Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-01-19 |
| Est. Completion | 2025-09-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04941573
The ClinicalTrials.gov registry entry for NCT04941573 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xemed, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hyperpolarized 129-Xenon (MagniXene) MRI of the lung is the first listed.
NCT04941573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04941573 about?
NCT04941573 is a clinical study titled "Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI". This study will use Magnetic Resonance Imaging (MRI) to study the lungs of 90 volunteers using the inhaled contrast agent, hyperpolarized xenon-129. Once inhaled, this gas can provide information to imagers regarding lung functionality across specific regions of the lungs by assessing the replacemen...
What is the current status of trial NCT04941573?
This trial is currently terminated. The enrollment target is 45 participants. The study started on 2021-01-19. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT04941573?
The interventions under investigation include: Hyperpolarized 129-Xenon (MagniXene) MRI of the lung (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04941573?
This trial is sponsored by Xemed, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.